Vascular endothelial growth factor (VEGF) is a heparin-binding, endothelial cell-specific mitogen. Previous studies have suggested that VEGF is a regulator ofnaturally occurring physiologic and pathologic angiogenesis. In this study we investigated the hypothesis that the angiogenic potential of VEGF is sufficient to constitute a therapeutic effect. The soluble 165-amino acid isoform ofVEGF was administered as a single intraarterial bolus to the internal iliac artery of rabbits in which the ipsilateral femoral artery was excised to induce severe, unilateral hind limb ischemia. Doses of 500-1,090 0,g of VEGF produced statistically significant augmentation of collateral vessel development by angiography as well as the number of capillaries by histology; consequent amelioration of the hemodynamic deficit in the ischemic limb was significantly greater in animals receiving VEGF than in nontreated controls (calf blood pressure ratio, 0.75±0.14 vs. 0.48±0.19, P < 0.05). Serial angiograms disclosed progressive linear extension of the collateral artery of origin (stem artery) to the distal point of parent vessel (reentry artery) reconstitution in seven of nine VEGF-treated animals. These findings establish proof of principle for the concept that the angiogenic activity of VEGF is sufficiently potent to achieve therapeutic benefit. Such a strategy might ultimately be applicable to patients with severe limb ischemia secondary to arterial occlusive disease. (J. Clin. Invest. 1994. 93:662-670.)
Introduction
Vascular endothelial growth factor (VEGF)' is a 45-kD heparin-binding dimeric glycoprotein that is mitogenic for endothelial cells (1) . VEGF is distinguished from other heparin-binding, angiogenic factors by several features. First, because its NH2 terminus is preceded by a typical signal sequence, VEGF can be secreted by intact cells (2) . Second, its binding sites, shown recently to include the tyrosine kinase receptorsflt (3) , fik-) (4) , and KDR (5) , are present in endothelial cells, quiescent as well as proliferating, but not in other cell types. Consequently, VEGF has been regarded as an endothelial cell-specific mitogen (6) (7) (8) .
Four different homodimeric species of VEGF have been identified, each monomer having 121, 165, 189, or 206 amino acids, respectively (9, 10) . Alternative splicing of the VEGF transcript, rather than transcription from different genes, is the most likely explanation for the existence of such multiple forms. While all four isoforms display activity in a Miles type of assay ( 11 ), i.e., extravasation of Evans blue dye in response to an intradermal injection, these four forms differ in their solubility characteristics. VEGF121 and VEGF165 are diffusible after secretion; VEGF189 and VEGF206 are secreted but are bound to heparin-containing proteoglycans in the cell surface or basement membrane ( 12) , and thus tend to remain cell associated ( 1 ). VEGF mRNA is expressed in a variety ofabundantly vascularized tissues. Furthermore, VEGF and VEGF receptors colocalize with sites of neovascularization in the female reproductive tract of rodents and primates (13) (14) (15) ; these observations were interpreted to suggest a role for VEGF in natural angiogenic processes within the female reproductive system. A similar temporal and spatial relationship has been observed between the ventricular neuroectoderm and capillaries from the perineural plexus in the mouse embryo (16) , and in highly vascularized human tumors (17) (18) (19) (20) .
Evidence that VEGF stimulates angiogenesis in vivo consists principally of experiments performed on rat and rabbit cornea (21, 22) , the chorioallantoic membrane (6) , and the rabbit bone graft model (22) . The angiogenic potential of VEGF was further inferred from studies in nude mice demonstrating that VEGF expression conferred upon Chinese hamster ovary cells the ability to form tumors (23) , and experiments in which monoclonal antibodies to VEGF were shown to inhibit tumor growth (24) .
Whether the magnitude of angiogenesis stimulated by VEGF in vivo is sufficient to constitute a potential therapeutic effect has not been previously tested. Accordingly, this investigation was designed to test the hypothesis that administration of VEGF in the setting of experimentally induced hind limb ischemia could stimulate angiogenesis and thereby modulate the hemodynamic deficit in the ischemic limb. The outcome of these in vivo experiments, performed in a rabbit model, suggests that a single intraarterial bolus of the 165-amino acid isoform of VEGF may have clinical use in the treatment of lower limb vascular insufficiency.
Methods
Animal model. The angiogenic response to intraarterial administration of VEGF in vascular insufficiency was investigated using a rabbit ischemic hind limb model (Fig. I) (25) . All protocols were approved by St. Elizabeth's Institutional Animal Care and Use Committee. A total of 16 male New Zealand White rabbits weighing 3-3.5 kg (Pine Acre Rabbitry, Norton, MA) were anesthetized with a mixture of ketamine (50 mg/kg) and acepromazine (0.8 mg/kg) after premedication with xylazine (2.5 mg/kg). A longitudinal incision was then performed, extending inferiorly from the inguinal ligament to a pointjust proximal to the patella. The limb in which the incision was performed (right vs. left) was determined at random at the time of surgery by the operator. Through this incision, using surgical loops, the femoral artery was dissected free, along its entire length; all branches of the femoral artery, including the inferior epigastric, deep femoral, lateral circumflex, and superficial epigastric arteries, were also dissected free. After further dissecting the popliteal and saphenous arteries distally, the external iliac artery as well as all ofthe above arteries were ligated (4.0 silk; Ethicon, Sommerville, NJ). Finally, the femoral artery was completely excised from its proximal origin as a branch of the external iliac artery, to the point distally where it bifurcates to form the saphenous and popliteal arteries.
Postoperation, all animals were closely monitored. Analgesia (60 mg/kg levorphanol tartrate; Roche Laboratories, Nutley, NJ) was administered subcutaneously as required for evidence of discomfort throughout the duration of the experiment. Prophylactic antibiotics ( 15 mg/kg sulfamethoxazole and 3 mg/kg trimethoprim; Elkins-Sinn, Cherry Hill, NJ) were also administered subcutaneously for a total of 5 d postoperatively.
Intraarterial VEGF administration. The 165-amino acid homodimeric species ofrecombinant human VEGF (rhVEGF,65) was purified from transfected Chinese hamster ovary cells as previously described (26) . The purity of the material was assessed by a silver-stained SDS/ PAGE gel and by the presence of a single NH2-terminal amino acid sequence.
At day 10 postoperation animals received VEGF or vehicle alone (saline with 0.1% rabbit serum albumin; Sigma Chemical Co., St. Louis, MO), in both cases delivered intraarterially. After performing a baseline angiogram (see below), a 3-French end-hole infusion catheter (Tracker-I8TM; Target Therapeutics, San Jose, CA) was positioned in the internal iliac artery ofthe ischemic limb, and then washed with 3 ml ofsaline containing 0.1% albumin. Next, either 500 jig (n = 4) or 1,000 jig (n = 5) of VEGF in 5 ml of saline containing 0.1% albumin was selectively delivered into the internal iliac artery as a bolus over a period of 1 min. Sham-treated animals, receiving an identical volume of saline with 0.1% albumin, but without VEGF protein, administered over 1 min, were used as controls (n = 7).
Evaluation ofangiogenesis in the ischemic limb. Development of collateral vessels in the ischemic limb was serially evaluated by calf blood pressure measurement and internal iliac arteriography immediately before treatment (day 10 postsurgery), and then in serial fashion at days 20 and 40 postsurgery (i.e., 10 and 30 d, respectively, postadministration of VEGF or vehicle control). On each occasion, it was necessary to lightly anesthetize the animal with a mixture of ketamine (10 mg/kg) and acepromazine (0.16 mg/kg) after premedication with xylazine (2.5 mg/kg). In the case of blood pressure measurements, pressure recorded from the contralateral, nonischemic limb controlled for any anesthesia-related fluctuations in blood pressure recordings. After the final 40-d angiogram, the animal was killed and tissue sections were prepared from the hind limb muscles in order to perform analysis of capillary density. These analyses were performed for both the control and VEGF-treated groups in relationship to surgery as follows. Control: day 0, surgery; day 10, BP/angio/saline; day 20, BP/angio; day 40, BP/angio/autopsy. VEGF treated: day 0, surgery; day 10, BP/angio/VEGF; day 20, BP/angio; day 40, BP/angio/autopsy.
Lower limb calfblood pressure ratio. Calf blood pressure was measured in both hind limbs using a Doppler Flowmeter ( 1050; Parks Medical Electronics, Aloha, OR), immediately before treatment (day 10), as well as on days 20 and 40. On each occasion, the hind limbs were shaved and cleaned, the pulse of the posterior tibial artery was identified using a Doppler probe, and the systolic blood pressures of both limbs were determined using standard techniques. Briefly, a 2.5-cm-wide cuff was applied over the upper calf, and the Doppler probe was placed over the posterior tibial artery. The cuffwas inflated rapidly to -30 mmHg above the anticipated systolic pressure. The cuff was then deflated slowly, no faster than 3 mm Hg/s. The first appearance of the Doppler flow signal (phase I) was recorded as the systolic pressure. Care was taken to prevent the rubber component of the cuff balloon from extending beyond its covering, and to prevent central ballooning due to loose cuff placement. All measurements were performed by a single observer blinded to the treatment regimen. The calf blood pressure ratio was defined for each rabbit as the ratio ofsystolic pressure of the ischemic limb to systolic pressure of the normal limb.
Selective internal iliac arteriography. Collateral artery development in this ischemic hind limb model originates from the internal iliac artery. Accordingly, selective internal iliac arteriography was performed on day 10 (before initiation of therapy), and again on days 20 and 40. The 3-French infusion catheter (Tracker-18.) was introduced into the right common carotid artery through a small cutdown, and advanced to the internal iliac artery of the ischemic limb using a 0.014-in guidewire (Hi-Torque Floppy II; Advanced Cardiovascular Systems, Temecula, CA) under fluoroscopic guidance. The tip of the catheter was positioned in the internal iliac artery at the level of the interspace between the seventh lumbar and the first sacral vertebrae. After intraarterial injection ofnitroglycerin (0.25 mg; SoloPak Laboratories, Franklin Park, IL), a total of 5 ml of contrast media (Isovue-370; Squibb Diagnostics, New Brunswick, NJ) was then injected using an automated angiographic injector (Medrad, Pittsburgh, PA) at a rate of 1 ml/ s. Serial images of the ischemic hind limb were then recorded on 105-mm spot film at a rate of one film per second for at least 10 s. After completion of arteriography, the catheter was removed and the wound was closed. All of the above-described procedures were completed without the use of heparin.
Quantitative angiographic analysis ofcollateral vessel development was performed as follows. A composite of 5-mm2 grids was placed over the medial thigh area of the 4-s angiogram. The total number of grid intersections in the medial thigh area, as well as the total number of intersections crossed by a contrast-opacified artery, were counted individually by a single observer blinded to the treatment regimen. An angiographic score was calculated for each film as the ratio of grid intersections crossed by opacified arteries divided by the total number of grid intersections in the medial thigh.
Capillary density and capillary/muscle fiber ratio. at this time, the blood pressure ratio for animals in the VEGFtreated group, however, was significantly higher than for animals in the control group (0.54±0.15 vs. 0.25±0.25, P < 0.05).
At day 40, the blood pressure ratio was further improved significantly in the VEGF-treated group (0.75±0.14, P < 0.01 vs. day 20), but not in the control group (0.48±0.19, P = NS vs. day 20) . Moreover, at day 40, the blood pressure ratio of the VEGF-treated group was significantly higher than that of control group (P < 0.05) (Fig. 2 a) . Angiographic assessment. Fig. 3 illustrates representative internal iliac angiograms recorded from both control and VEGF-treated animals. In control animals, collateral artery development in the medial thigh typically appeared unchanged or progressed only slightly in serial angiograms recorded at days 10, 20, and 40 ( Fig. 3, a-c) . In contrast, in the VEGFtreated group, improvement of collateral artery development was typically observed in angiograms at days 20 and 40 when compared with the baseline (day 10) angiogram (Fig. 3, d-f ).
Distal arterial reconstitution, barely apparent in control group (Fig. 3, b and c, arrows), was readily seen in the VEGF-treated group (Fig. 3, e eral vessel development in the medial thigh was performed by calculating the angiographic score as described above. At baseline (day 10), before treatment, there was no significant difference in angiographic score between the VEGF-treated and control groups (0.20±0.09 vs. 0.21±0.09, P = NS). By days 20 and 40, however, the angiographic score in VEGF-treated group was significantly higher than that in control group (day 20:
0.36±0.06 vs. 0.23+0.06, P < 0.001; day 40: 0.37±0.08 vs.
0.24±0.05, P < 0.01) (Fig. 2 b) . Although a progressive increase in angiographic score was observed between days 10 and 40 in both groups, that measured for the control group was not statistically significant. The increase calculated for the VEGFtreated group was significant between days 10 and 20 (P < 0.001), but not between days 20 and 40. As shown in Fig. 4 b, the magnitude of improvement in angiographic score was not dependent upon the dose (500 or 1,000 ,g) of VEGF used.
Instead, the increase in angiographic score at day 20 was inversely related to the angiographic score at the time of VEGF administration (day 10) (r = -0.97, P < 0.001). Although a similar relationship was observed in control group (Fig. 4 a) , the magnitude of improvement in angiographic score at day 20 was small even in those animals having a low angiographic score at baseline (day 10) (r = -0.73, P = 0.06). In both groups, the morphology ofthe augmented collateral circulation included fine networks of so-called mid-zone collateral vessels (30) (Fig. 3) . In addition, serial angiograms disclosed progressive linear extension of the stem (internal iliac) artery to the reentry (popliteal or saphenous arteries) in seven (78%) ofthe nine VEGF-treated animals. In contrast, such direct linear extension was observed in only two (29%) of seven controls (P < 0.05) (Fig. 3, b , c, e, andf, open arrows). Capillary density and capillary/musclefiber ratio. To further evaluate the effect of intraarterial VEGF administration upon revascularization of the ischemic hind limb, the medial thigh muscles of the ischemic limbs were histologically examined at day 40 as described above. For muscles in the VEGFtreated group, capillary density measured 2.5 times that measured for the control group (230.8±39.1 vs. 83.1 ±31.4/mm2, P < 0.001) (Fig. 2 c) . Analysis of capillary/muscle fiber ratio disclosed a value of 0.76±0.06 in the VEGF-treated group vs. 0.36±0.08 in the control group (P < 0.001). Light microscopic signs of frank myonecrosis were not observed in either group.
Discussion
The therapeutic implications ofangiogenic growth factors were defined by the pioneering work of Folkman and colleagues over two decades ago (31) . Their work documented the extent to which tumor development was dependent upon neovascularization and suggested that this relationship might involve angiogenic growth factors that were specific for neoplasms. Subsequent studies established that a common group of polypeptide growth factors were responsible for natural as well as pathologic angiogenesis.
The identification and characterization of VEGF followed a similar course. Initially isolated as a heparin-binding secreted factor from bovine pituitary folliculo-stellate cells (6) , VEGF was also purified independently as a tumor-secreted factor that induced vascular permeability by the Miles assay (32, 33) . Data accumulated from a variety of previous studies support the role of VEGF in embryogenesis (4), wound healing (19) , and ovulation (13) (14) (15) . Recent experimental work performed reconstruction. Therapeutic angiogenesis thus constitutes a poAngiographic score at day 10 tential alternative treatment strategy for such patients.
The strategy used in the current series of experiments was designed to exploit certain features of the 165-amino acid VEGF species, the predominant molecular form found in nor-5-_ mal cells and tissues (9, 36 relative to VEGF,89 and VEGF206, VEGF,65 still demonstrates experimental model (25) used in this study was desubstantial affinity for heparin (more, for example, than simulate ischemia characteristic of patients with se-VEGF,21); in fact, previously published data by Houck et al.
er extremity arterial occlusive disease. In contrast to ( 12) indicate that up to 50% of VEGF,65 is retained extracellu-)f acute ischemic injury (29, 34) , an interval of 10 d larly by heparin-binding proteoglycans. the time of surgery and initiation of administration of VEGF contrasts with most previously described angiogenic ,as incorporated to allow for endogenous recovery and growth factors in that its high affinity receptors appear limited [ion. Baseline angiography documented that this I0-d to endothelial cells. In contrast to other angiogenic growth facwas sufficient for development of varying degrees of tors, including acidic and basic FGF, which are known to be ous collateral vessel formation. The notion that the mitogenic for smooth muscle cells (37, 38) and fibroblasts as tnimal model simulates "chronic" ischemia is further well as endothelial cells, the fact that the mitogenic activity of d by the finding that collateral vessel development did VEGF is limited to endothelial cells constitutes a theoretical rove significantly beyond this point, up to the time of advantage for angiogenesis strategies designed to treat vascular ,iography and death at 40 d (Fig. 3) . Indeed, initial insufficiency.
valuating this model (25) demonstrated no significant Although heparin is often administered prophylactically aeous" improvement in collateral perfusion either anduring percutaneous arterial catheterization, the use ofheparin tically or hemodynamically between days 30 and 90
was explicitly avoided during all diagnostic angiograms and/or gically induced ischemia.
catheter-based delivery of VEGF in the current series ofexperi- Ag/ml of heparin. Future experiments will evaluate the angiogenic response of VEGF, administered with heparin, in this same animal model. Evidence ofangiogenesis (44) in response to VEGF administration was observed at two levels. Necropsy examination documented an increase in vascularity at the capillary level, consistent with the classical definition of angiogenesis espoused by Klagsbrun and Folkman (44) . In addition, systematic quantification of angiographic recordings performed serially at 10, 20, and 40-d postoperation demonstrated that development of angiographically visible collateral arteries in the VEGF-treated animals exceeded that observed in the control group, both at days 20 and 40. From an anatomic standpoint, angiographic improvement in the treatment group appeared restricted to the 10 d after administration of VEGF, after which a plateau was observed for the subsequent 20-d period. Moreover, while the number ofanimals studied and the doses of VEGF used have to date been limited, the magnitude of improvement in angiographic score nevertheless appeared to be independent of the dose of VEGF used; instead, angiographic score improved as a function of the severity of baseline angiopenia. This finding raises the possibility that hypoxia, in addition to upregulating transcription ofVEGF mRNA (45) , may also result in upregulation of endothelial cell receptors for VEGF. A similar relationship, albeit with a much flatter slope, was demonstrated for the control animals, in which the ultimate increase in angiographic score was far more limited. The principal angiographic finding accounting for the increase in angiographic score observed in the VEGF-treated group was an increase in so-called mid-zone collateral vessels (30) , consistent with the definition of angiogenesis cited above. Furthermore, in most VEGFtreated animals, vs. only a few controls, this was accompanied by progressive linear extension of the artery of origin (stem artery) to the distal point of parent vessel reconstitution (reentry artery). Subsequent study will be required to determine whether this angiographic feature is a distinct consequence of therapeutic vs. natural angiogenesis in this animal model of circulatory insufficiency.
The physiologic correlate of these angiographic findings, and thus the extent to which angiogenesis was therapeutic, was assessed by serial measurement of the lower limb blood pressure ratio. Both at days 20 and 40, this ratio in the VEGFtreated group exceeded significantly the same ratio measured in the control group. The temporal evolution of hemodynamic improvement did not altogether parallel the temporal sequence of improvement in angiographic score noted above. VEGF administration, for example, produced a statistically significant increase in angiographic score between the baseline (day 10) examination and the first follow up angiogram (day 20); this was accompanied by a significant increase in lower limb blood pressure ratio. From days 20 to 40, VEGF produced no further improvement in angiographic score; during this same period of time, however, calf blood pressure ratio continued to improve to a statistically significant degree. In the control group, serial angiographic examinations failed to show significant improvement in collateral artery development after the baseline study; hemodynamic findings did improve, although never to the significant degree observed in the VEGF-treated animals. The secondary improvement in calf blood pressure ratio between days 20 and 40 in the VEGF-treated group, as well as the more modest improvement shown for the control group, appeared to result from an increase in size, rather than number, of collateral vessels (Fig. 3) .
This study was not intended to determine the extent of fluid extravasation resulting from VEGF administration, and, accordingly, no tracer studies were included in the experimental design. Light microscopic observations, however, failed to disclose evidence of interstitial edema formation observed in those animals receiving VEGF. Although experimental use of the Miles assay has clearly suggested that VEGF selectively augments vascular permeability (12, 17, 32, 33) , the significance ofthis finding remains unclear pending further analyses.
In summary, the anatomic and physiologic findings observed after administration of VEGF165 in an experimental model ofcirculatory insufficiency establishes proof ofprinciple for the concept that the angiogenic activity of VEGF is sufficiently potent to constitute a therapeutic effect. Further investigation may clarify the extent to which use of VEGF may be appropriate for treatment of selected patients with advanced lower extremity vascular occlusive disease.
